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Edited by Peter BrzezinskiAbstract Coagulation factor VIIa (FVIIa) belongs to a family
of proteases being part of the stepwise, self-amplifying blood
coagulation cascade. To investigate the impact of the mutation
Met298{156}Lys in FVIIa, we replaced the Gly283{140}–
Met298{156} loop with the corresponding loop of factor Xa. The
resulting variant exhibited increased intrinsic activity, concur-
rent with maturation of the active site, a less accessible N-termi-
nus, and, interestingly, an altered macromolecular substrate
speciﬁcity reﬂected in an increased ability to cleave factor IX
(FIX) and a decreased rate of FX activation compared to that
of wild-type FVIIa. In complex with tissue factor, activation of
FIX, but not of FX, returned to normal. Deconvolution of the
loop graft in order to identify important side chain substitutions
resulted in the mutant Val158{21}Asp/Leu287{144}Thr/Ala294{152}-
Ser/Glu296{154} Ile/Met298{156}Lys-FVIIa with almost the same
activity and speciﬁcity proﬁle. We conclude that a lysine residue
in position 298{156} of FVIIa requires a hydrophilic environment
to be fully accommodated. This position appears critical for sub-
strate speciﬁcity among the proteases of the blood coagulation
cascade due to its prominent position in the macromolecular exo-
site and possibly via its interaction with the corresponding posi-
tion in the substrate (i.e. FIX or FX).
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Coagulation factor VIIa (FVIIa) is a serine protease that
plays a central role in the initiation of the blood coagulation
cascade of the vascular hemostatic system. FVIIa in complex
with tissue factor (TF) at a site of vascular injury initiates coag-
ulation by activation of factors IX (FIX) and X (FX). FIX andAbbreviations: AT, antithrombin; FIX(a), factor IX(a); FVIIa, factor
VIIa; FVIIaIIa, FVIIa variant Val
158{21}Asp/Glu296{154}Val/Me-
t298{156}Gln; FVIIaDIK, FVIIa variant Val
158{21}Asp/Glu296{154}Ile/
Met298{156}Lys; FVIIaDTSIK, FVIIa variant Val
158{21}Asp/Leu287{144}-
Thr/Ala294{152}Ser/Glu296{154}Ile/Met298{156}Lys; FVIIaFXLoop, FVIIa
variant with residues 283{140}–298{156} replaced by the correspond-
ing residues from FX together with mutations Val158{21}Glu,
Gln176{40}Gly and Lys341{192}Gln; FX(a), factor X(a); TF, tissue factor
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doi:10.1016/j.febslet.2006.11.079FX activation subsequently lead to thrombin generation, which
in turn cleaves ﬁbrinogen to ﬁbrin. By cross-linking of ﬁbrin by
activated factor XIII, a strong clot is produced that restores
vascular integrity and ﬂow. All proteases of the coagulation
cascade are secreted as zymogens and need proteolytic cleavage
of the peptide bond preceding position {16} (trypsinogen num-
bering in brackets) and in some cases association with their cog-
nate cofactor to be catalytically and biologically active. For
FVIIa, association with TF facilitates insertion of the N-termi-
nal Ile{16} into the activation pocket and establishment of a salt
bridge with Asp{194} which is adjacent to the active site residue
Ser{195} [1]. This is not only a common feature for the serine
proteases in the coagulation cascade, but is also the canonical
allosteric mechanism for all trypsin-like serine proteases [2,3].
FVIIa only gains full activity upon Ca2+-dependent association
with TF and binding of Ca2+ to the loop Glu210{70}–Glu220{80}
in the protease domain [4–7]. In the free form, FVIIa mainly re-
mains in a zymogen-like state with low catalytic eﬃciency.
Macromolecular substrate interactions at exosites, sites
within the FVIIaÆTF complex distant from the active site of
FVIIa, determine aﬃnity and speciﬁcity in the productive rec-
ognition of FX [8,9]. At one of these sites, Met298{156} has been
shown to be a key determinant for maintaining free FVIIa in
the zymogen-like state [10,11]. Site-directed mutagenesis stud-
ies have demonstrated that replacement of Met298{156} with
glutamine, which occupies the corresponding position in FIXa
and thrombin, renders FVIIa intrinsically more active with en-
hanced turnover of FX [10–13]. Surprisingly, introduction of a
lysine, as found in the homologous FXa, results in a protein
with apparently diminished activity [11]. The Met298{156} resi-
due is located within the loop Gly283{140}–Met298{156}, which
acts as an allosteric modulator of FVIIa [10–13]. It is part of
the activation domain which has been shown to undergo con-
formational changes in the trypsinogen to trypsin transition
[3,14]. Accordingly, we have observed using a molecular
dynamics simulation that upon extraction of the N-terminus
from the activation pocket the loop becomes markedly disor-
dered (O.H. Olsen, unpublished results).
Soejima and colleagues performed grafting of the loops
Thr233{93}–Asp242{102} and Cys310{168}–Cys329{182}, inserting
the loops of trypsin, to obtain FVIIa molecules with signiﬁ-
cantly higher amidolytic activities and an impaired eﬀect of
TF binding, but with no eﬀect on N-terminus burial [15,16].
In our laboratory, mutagenesis in the Cys310{168}–Cys329{182}
loop has also led to proteins with increased amidolytic activi-
ties [17].blished by Elsevier B.V. All rights reserved.
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ity, but also for insights into macromolecular substrate speciﬁc-
ity. Since lysine and glutamine are found in position {156} in a
number of members of the trypsin family of serine proteases, we
aimed at exploring the molecular environment in FVIIa re-
quired to accommodate a lysine in position 298{156} using ra-
tional loop grafting and site-directed mutagenesis. We obtained
Met298{156}Lys-FVIIa variants with increased intrinsic activity
but at the same time with either an enhanced (with FIX) or
diminished (with FX) proteolytic activity relative to wild-type
FVIIa. Structural models of FVIIa/FXa complexes indicate
that the close vicinity of the side chains of Lys298{156} in the
FVIIa variants and the corresponding position in the substrate
(FIX or FX) generates an electrostatic repulsion when the sub-
strate is FX (Lys378{156}), while a favourable interaction is seen
with FIX (Gln370{156}) [18, O. H. Olsen, unpublished data].2. Materials and methods
2.1. Protein preparations
A restriction digest cassette system, DraIII and BstZ17I, was intro-
duced by means of site-directed mutagenesis into the pZym219b vector
harboring the full-length cDNA of FVII at position bp
1099{Aa272{129C}} and 1192{Aa303{161}}. This allowed for easy
insertion of a loop graft by means of subcloning of annealed oligonu-
cleotides. The following oligonucleotides were used for the construc-
tion of the loop graft, for introduction of site-speciﬁc mutations and
for the cloning cassette (amino acid and nucleotide changes indicated
with underline and italic, respectively):
Val158{21}Asp: C CGA ATT GTG GGG GGC AAG GAC TGC
CCC AAA GGG GAG TGT CC. Val158{21}Glu: GA ATT GTG
GGG GGC AAG GAG TGC CCC AAA GGG GAG TGT CC.
Gln176{40}Gly: G TTG TTG GTG AAT GGA GCT GGG TTG
TGT GGG GGG ACC CTG ATC. Lys341{192}Gln: GGC AGC
AAG GAC TCC TGC CAG GGG GAC AGT GGA GGC CC.
Leu287{144}Thr/Ala294{152}Ser/Glu296{154}Ile/Met298{156}Lys: G GTC
AGC GGC TGG GGC CAG ACG CTG GAC CGT GGC GCC
ACG TCC CTG ATT CTC AAG GTG CTC AAC GTG CCC
CGG C. Glu296{154}Ile/Met298{156}Lys: GGC GCC ACG GCC CTG
ATT CTC AAG GTC CTC AAC GTG CCC C. DraIII_cas: GG
ACG TTC TCT GAG AGG ACACTG GGTGTC GTG CGC TTC
TCA TTG G. BstZ17I_cas: G CTC ATG GTC CTC AGT ATA
CCC CGG CTG ATG ACC CAG GAC TGC. FXLoopFVII: CC
TTC GTG CGC TTC TCA TTG GTC AGC GGG TTT GGG
CGT ACT CAT GAA AAA GGG CGT CAA TCT ACT CGT
CTT AAA GTC CTC AAC G. FXLoopFVII(COMP): C GTT GAG
GAC TTT AAG ACG AGT AGA TTG ACG CCC TTT TTC
ATG AGT ACG CCC AAA CCC GCT GAC CAA TGA GAA
GCG CAC GAA GGC CA. FVII wild-type/variants were expressed
using CHO K1 and BHK-producing cells, recombinant proteins puri-
ﬁed and zymogens activated essentially as described [10,19]. Active site
titration by means of irreversible inhibition using the PhePheArg chlo-
romethylketone was employed to determine the active enzyme fraction
after activation essentially as described [20].
FX and FIX were from Enzyme Research Laboratories. Soluble TF
was produced as described [21]. Antithrombin (AT) was from Hema-
tologic Technologies (Essex Junction, VT).2.2. Amidolytic activity assay
The amidolytic activity of variant/wild-type FVIIa (100 nM) with or
without 1 lM soluble TF were measured at room temperature in
microtiter plates. The assay buﬀer used was 50 mM Hepes, pH 7.4,
containing 0.1 M NaCl, 5 mM CaCl2, and 1 mg/ml BSA. Initial activ-
ity rates were determined from absorbance (405 nm) development
using the chromogenic substrates S-2288 (1 mM) (H-D-Ile-Pro-Arg-
pNA, Chromogenix) and S-2238 (1 mM) (H-D-Phe-Pip-Arg-pNA,
Chromogenix), and monitored for 5–30 min with readings every 30 s
in a kinetic SpectraMax 340 microplate reader (Global Medical Instru-
mentation Inc., Minnesota, USA).2.3. FX activation assay
FX activation was assayed by incubating 100 nM variant/wild-type
FVIIa with or without 1 lM soluble TF with 0–0.5 lM FX in 50 ll
of assay buﬀer (see Amidolytic activity assay) for 20 min at room tem-
perature. 150 ll assay buﬀer containing 20 mM EDTA instead of
CaCl2 was added to quench the FX activation process, followed by
the addition of 50 ll of 2.5 mM FX substrate S-2765 (Z-D-Arg-Gly-
Arg-pNA, Chromogenix). The rate of S-2765 hydrolysis was moni-
tored for 2–5 min during which the absorbance increase was linear.
2.4. FIX activation assay
FIX activation was assayed by incubating 0.2–1 lM variant/wild-
type FVIIa with or without 5 lM soluble TF with 0–0.5 lM FIX in
100 ll of assay buﬀer (see Amidolytic activity assay) for 1–2 h at room
temperature. One hundred microliter assay buﬀer containing 20 mM
EDTA, 60% ethylene glycol, 1 mM substrate CBS31.39 (CH3SO2-D-
Leu-Gly-Arg-pNA, Diagnostica Stago) was added and mixed thor-
oughly to quench the FIX activation process and to initiate FIXa
measurement. The rate of CBS31.39 hydrolysis was monitored for 2–
5 min during which the absorbance increase was linear.2.5. Carbamylation assay
The carbamylation of Ile153{16} was performed by incubation of
2 lM to 100 nM variant/wild-type FVIIa with 0.2 M potassium cya-
nate in assay buﬀer (see Amidolytic activity assay) without BSA for
0–120 min. Samples were redrawn at diﬀerent time points and diluted
10-fold in assay buﬀer containing 5 mM S-2288 (H-D-Ile-Pro-Arg-
pNA, Chromogenix) and hydrolysis was monitored for 2–5 min (in a
similar fashion as described for the amidolytic assay).
2.6. AT inhibition assay
AT inhibition was performed by incubation of 100 nM variant/wild-
type FVIIa with 100 lg/ml AT and 1 unit/ml heparin in assay buﬀer for
0–45 min. Samples were redrawn at diﬀerent time points and diluted 2-
fold in assay buﬀer containing 5 mM S-2288 (H-D-Ile-Pro-Arg-pNA,
Chromogenix) and hydrolysis was monitored for 2–5 min.3. Results and discussion
3.1. Molecular design
Based on structure and sequence homologies among the ser-
ine proteases of the blood coagulation cascade, we designed
diﬀerent FVIIa constructs with the Met298{156}Lys substitution
to address both activity and macromolecular substrate selectiv-
ity. We focused on the 298{156} position within the
Gly283{140}–Met298{156} loop (see Fig. 1), since previous studies
have shown that residues within this region, including
Glu296{154}, constitute part of the macromolecular substrate
exosite and are determinants for the zymogen-like conforma-
tion involved in the allosteric activation of FVIIa via insertion
of the N-terminus [11,12]. Rational mutagenesis of speciﬁc res-
idues surrounding the N-terminus has led to FVIIa variants,
which all included the Met298{156}Gln substitution, with higher
catalytic turnover of FX and of small peptidyl substrates [10–
13]. The explanation for this is presumably that the
Met298{156}Gln mutation tethers the N-terminus via an ex-
panded hydrogen bonding network.
In analogy to the Met298{156}Gln mutation in FVIIaIIa
(Val158{21}Asp/Glu296{154}Val/Met298{156}Gln), the corresponding
lysine mutation is believed to be able to support a similar
hydrogen bond network. However, apparently it is not in itself
suﬃcient as the single mutant shows diminished activity, at
least in complex with TF [11]. To try to design a FVIIa variant
with higher activity containing the mutation Met298{156}Lys,
we designed a FXa loop graft construct. From structural
superimposition of the crystal structures of FVIIa and FXa,
Fig. 1. Structure and sequence alignment of FVIIa and FXa. (A) Top: Superimposition of the protease domains of FVIIa (grey; pdb id. 1DAN) and
FXa (yellow; pdb id. 1XKA). The grafted loop 283{140}–298{156} is indicated together with the key allosteric switch residue 298{156} (FVIIa,
methionine; FXa, lysine), the Ca2+-binding loop 210{70}–220{80} and the N-terminus with the salt bridge between Ile153{16} and Asp343{194}
(residues not shown). The Ca2+ ion in the protease domain is shown as a green sphere. Note that the disordered parts (high crystallographic
temperature factors) of loops Ala330{183}–Ser339{190} and Gln366{217}–Phe374{225} adjacent to the N-terminus of FVIIa, are not present in the
analogous loops of FXa. Bottom: sequence alignment of the grafted loop 283{140}–298{156}. Shaded boxes indicate full identity, while underlines
indicate performed mutations. (B) and (C) highlight important substitutions surrounding the 298{156} position. Wild-type FVIIa (B, pdb id. 1DAN)
and a model of FVIIaFXLoop with optimized rotamer conformations (C) are shown. Arrows indicate the N-terminal tail. In B, the loop of FVIIa is
shown with the centrally positioned Met298{156} engaged in a solvent exposed, hydrophobic patch composed of Val158{21}, Leu287{144} and Ala294{152}
with no energetically beneﬁcial interaction with the outmost part of the N-terminal tail. In (C), the 298{156} Lys engages in a hydrogen bond
network with the substituted polar Leu287{144}Thr and Ala294{152}Ser, which have direct impact on the outmost part of the N-terminal tail (water
molecules identiﬁed in the FVIIa structure that could engage in hydrogen bonding network are shown). Thus, Met298{156}Lys is packed in a
hydrophilic environment, which was utilized in the design of FVIIaDTSIK. The mutations Val
158{21}Glu, Gln176{40}Gly and Lys341{192}Gln were
introduced into FVIIaFXLoop because of unfavourable interactions with Glu
296{154}Arg, Thr293{151}Gln and Gln286{143}Arg, respectively.
Interestingly, the acidic residue Glu296{154} of FVIIa has a basic counterpart (Arg376{154}) in FXa, which in FVIIa, from an activity point of
view, is most optimally substituted with a hydrophobic residue as found in thrombin [10,12]. The same is the case for the mutation Val158{21}Glu. In
FVIIaDTSIK, the Val
158{21}Asp mutation was utilized in analogy to FVIIa variant Val158{21}Asp/Glu296{154}Val/Met298{156}Gln providing the same
functionality as Val158{21}Glu in FVIIaFXLoop.
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residues of the inserted loop and the surrounding activation
pocket of FVIIa which required optimization (Fig. 1). Because
of unfavourable interactions with Glu296{154}Arg,
Thr293{151}Gln and Gln286{143}Arg, three repair mutations
(Val158{21}Glu, Gln176{40}Gly and Lys341{192}Gln) were intro-
duced in addition to loop graft (Fig. 1). The resulting FVIIa
variant, FVIIaFXLoop, possessed increased intrinsic activity
and changed macromolecular substrate speciﬁcity (see below).Two of the compensatory mutations were introduced at posi-
tions reported to inﬂuence substrate processing (Gln176{40}
[8] and Lys341{192} [22]). However, we believe that the Arg side
chain in position 286{143} of FVIIaFXLoop replaces that of
Lys341{192}, and that the amide of Gln293{151} replaces that of
Gln176{40}, thereby silencing the two compensatory mutations.
The indistinguishable activities of FVIIaFXLoop and FVIIaDTSIK
(FVIIa variant Val158{21}Asp/Leu287{144}Thr/Ala294{152}-
Ser/Glu296{154}Ile/Met298{156}Lys), with the latter having the
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indeed the situation and that the repair strategy was successful.
In addition, a triple mutant (Val158{21}Asp/Glu296{154}-
Ile/Met298{156}Lys-FVIIa (FVIIaDIK)) and a penta mutant
(Val158{21}Asp/Leu287{144}Thr/Ala294{152}Ser/Glu296{154}Ile/
Met298{156}Lys-FVIIa (FVIIaDTSIK)) were constructed to iden-
tify the (most) important substitutions in FVIIaFXLoop. Both
variants resemble the superactive mutant FVIIa variant
Val158{21}Asp/Glu296{154}Val/Met298{156}Gln previously char-
acterized in our laboratory [10,13] in that they address amino
acid changes of and in the vicinity of residue 298{156}.
3.2. Production of FVIIa variants
FVIIaFXLoop, FVIIa variant Val
158{21}Asp/Leu287{144}Thr/
Ala294{152}Ser/Glu296{154}Ile/Met298{156}Lys and FVIIa variant
Val158{21}Asp/Glu296{154}Ile/Met298{156}Lys were expressed
and puriﬁed to homogeneity, giving distinct bands at 50 kDa
on SDS–PAGE stained with Coomassie Blue (not shown).
FVIIa variant Val158{21}Asp/Leu287{144}Thr/Ala294{152}Ser/
Glu296{154}Ile/Met298{156}Lys and FVIIaFXLoop were fully acti-
vated by means of autoactivation at a concentration of more
than 0.5 mg/ml as judged from reduced SDS–PAGE analysis
and were almost completely converted to the two-chain forms
during puriﬁcation. FVIIa variant Val158{21}Asp/
Glu296{154}Ile/Met298{156}Lys behaved more like wild-type
FVIIa and was fully activated only upon incubation with
Sepharose-coupled FXa after puriﬁcation.
3.3. Amidolytic activity
Amidolytic activities were measured using two diﬀerent p-
nitroanilide peptidyl substrates, S-2288 (H-D-Ile-Pro-Arg-
pNA) and S-2238 (H-D-Phe-Pip-Arg-pNA). FVIIaFXLoop
and FVIIaDTSIK displayed 4–8-fold higher amidolytic activities
compared to wild-type FVIIa depending on substrate (Table
1). This is similar to FVIIa variant Val158{21}Asp/Glu296{154}-
Val/Met298{156}Gln, which showed 5–7-fold higher activity as
previously published [10]. Thus, FVIIa variant Val158{21}Asp/
Leu287{144}Thr/Ala294{152}Ser/Glu296{154}Ile/Met298{156}Lys re-
tained the high level of activity observed for the loop graft mu-
tant FVIIaFXLoop. Neither of the mutants showed signiﬁcantly
higher activity when in complex with soluble TF compared to
wild-type FVIIa, indicating that the eﬀects of the mutations
are part of, or overruled by, the eﬀects induced by cofactor
binding (data not shown). FVIIa variant Val158{21}Asp/
Glu296{154}Ile/Met298{156}Lys showed a reduced amidolytic
activity of approx. 70% of wild-type and thus was not analyzed
further. The results with FVIIa variant Val158{21}Asp/
Glu296{154}Ile/Met298{156}Lys demonstrates that a Lys residue
in position 298{156} of FVIIa per se does not induce an activ-
ity enhancement, which was theoretically conceivable based
on the role of the corresponding residue in the zymogen activ-Table 1
Enzymatic activities without TF relative to wild-type FVIIa (set to 1)
Amidolytic activity
(DA405/min)
Proteolytic activity
(kcat/Km)
S-2288 S-2238 Factor IX Factor X
Wild-type 1.0 1.0 1.0 1.0
FVIIaFXLoop 8.10.1 3.81.2 4.31.3 0.50.1
FVIIaDTSIK 8.70.6 6.11.0 5.71.0 0.50.3
FVIIaDIK 0.70.1 n.d. n.d. n.d.ity of tissue-type plasminogen activator [23]. Moreover,
there is no reason to assume that this Lys residue contributes
to the increased activities of FVIIaFXLoop and FVIIa
variant Val158{21}Asp/Leu287{144}Thr/Ala294{152}Ser/Glu296{154}-
Ile/Met298{156}Lys by a direct interaction with Asp343{194}
especially considering that these two FVIIa variants have a
Thr residue in position 287{144} as in FX [23].3.4. Active site maturation and N-terminus accessibility as
judged from AT inhibition and carbamylation of Ile153{16}
The susceptibility of TF-bound FVIIa to inhibition by AT
has been shown to be 33-fold enhanced compared to free
FVIIa as a result of maturation of the active site [4,24]. Thus,
changes in AT inhibition kinetics can be used to assess the
state of the active site. Previous studies of FVIIa variant
Val158{21}Asp/Glu296{154}Val/Met298{156}Gln and other vari-
ants with higher intrinsic activities have shown a correlation
between a faster rate of inhibition by AT and a higher level
of intrinsic amidolytic activity of the enzyme [10]. We observed
3.5-fold and 3-fold faster inhibition of FVIIaFXLoop and FVIIa
variant Val158{21}Asp/Leu287{144}Thr/Ala294{152}Ser/
Glu296{154}Ile/Met298{156}Lys, respectively, compared to wild-
type FVIIa (Fig. 2), supporting a maturation of the active site
with improved substrate accommodation. FVIIa variant
Val158{21}Asp/Glu296{154}Val/Met298{156}Gln was included for
comparison and was inhibited 4.5 times faster (data not
shown).
Chemical modiﬁcation of the N-terminal Ile153{16} of FVIIa
by means of carbamylation is a way of assessing the extent of
burial in the activation pocket. In essence, the more buried an
N-terminus, the less susceptibility to modiﬁcation and result-
ing reduction of enzymatic activity. This has been shown to
correlate with activity and TF binding in the sense that the ac-
tive conformation of FVIIa has a more buried N-terminus
[25,26], and enhanced burial of the N-terminus induced by
mutagenesis has been shown to be accompanied by a shift in
the equilibrium of FVIIa from a zymogen-like towards a cata-
lytically competent conformation [10]. Carbamylation wasFig. 2. Antithrombin inhibition assay. The residual activity of wild-
type FVIIa (¤), FVIIaDTSIK (n) and FVIIaFXLoop (m) after indicated
incubation times with antitrombin is shown. The curves show the
result of a representative experiment (n = 3).
Fig. 3. Carbamylation assay. The residual activity of wild-type FVIIa
(r), FVIIaDTSIK (n) and FVIIaFXLoop (m) after indicated incubation
times with KOCN is shown. The curves show the result of a
representative experiment (n = 3).
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in FVIIaFXLoop and FVIIa variant Val
158{21}Asp/
Leu287{144}Thr/Ala294{152}Ser/Glu296{154}Ile/Met298{156}Lys. The
carbamylation rate was decreased about 2-fold for both
variants compared to that of wild-type (Fig. 3), indicating a
more inserted N-terminus. Thus, the higher intrinsic activities
of the two FVIIa variants concur with a higher degree of
burial of the N-terminus as seen previously for FVIIa variant
Val158{21}Asp/Glu296{154}Val/Met298{156}Gln. Hence, the hydro-
gen bonding network surrounding the N-terminus in the acti-
vation pocket appears to be stabilized also after introduction
of a lysine in position 298{156}.3.5. Proteolytic activity
The ability to proteolytically activate the zymogens FIX and
FX was quantiﬁed by determining kcat/Km [27]. In the free
form, FVIIaFXLoop showed a 4.3-fold higher cleavage rate of
FIX than FVIIa (Table 1), whereas in complex with soluble
TF, FVIIaFXLoop and FVIIa cleaved FIX at equal rates. Inter-
estingly, a 2-fold slower activation rate of FX compared to
that of FVIIa was observed both in the presence and absence
of TF, indicating that activation was compromised upon loop
grafting. FVIIa variant Val158{21}Asp/Leu287{144}Thr/
Ala294{152}Ser/Glu296{154}Ile/Met298{156}Lys exhibited the same
proﬁle, with a 5.7-fold faster activation of FIX (also only in the
free form) and a 2-fold slower activation of FX both in the ab-
sence and presence of soluble TF (Table 1). Free FVIIa variant
Val158{21}Asp/Glu296{154}Val/Met298{156}Gln appeared to
cleave both macromolecular substrates at increased rates com-
pared to wild-type FVIIa, whereas FVIIa variant
Val158{21}Asp/Glu296{154}Val/Met298{156}Gln bound to soluble
TF was indistinguishable from FVIIa [10]. The increased abil-
ity to activate FIX compared to FX observed for FVIIaFXLoop
and FVIIa variant Val158{21}Asp/Leu287{144}Thr/Ala294{152}-
Ser/Glu296{154}Ile/Met298{156}Lys is interesting and shows
that the Gly283{140}–Met298{156} loop helps to deﬁne the macro-
molecular substrate exosite speciﬁcity in agreement with previ-
ous data [8,10,28]. Inspection of the diﬀerences betweenFVIIaFXLoop or FVIIa variant Val
158{21}Asp/Leu287{144}Thr/
Ala294{152} Ser/Glu296{154}Ile/Met298{156}Lys and FVIIa
variant Val158{21}Asp/Glu296{154}Val/Met298{156}Gln reveals
residues that determine the speciﬁcity among the coagulation
factors. The Met298{156}Lys mutation appears to have a central
role, while the mutations Val158{21}Asp and Glu296{154}Ile
presumably act as in FVIIa variant Val158{21}Asp/Glu296{154}-
Val/Met298{156}Gln and increase the catalytic eﬃciency by
stabilizing the catalytically competent state of FVIIa via burial
of the N-terminus in the activation pocket. A hydrophilic
glutamine residue in the 298{156} position, as in factor IXa
and in the majority of chymotrypsin-like serine proteases,
results in an improved ability to activate both FX as previously
reported [10–13] and FIX. Whereas the same eﬀect on the two
macromolecular substrates is achieved with glutamine, the
introduction of a positive charge via the Met298{156}Lys muta-
tion apparently hampers FX activation. The two hydrophilic
substitutions Leu287{144}Thr and Ala294{152}Ser cannot be
ruled out as being important for the diﬀerential eﬀect as well.
However, these two residues appear to be necessary for opti-
mal accommodation of lysine in the 298{156} position.3.6. Speculation
We show in this study, that by replacing Met298{156} in
FVIIa with Lys and providing the new side chain with an opti-
mal environment, a positive eﬀect on catalytic turnover and
an altered macromolecular substrate speciﬁcity is obtained.
Since only FVIIaFXLoop and FVIIa variant Val
158{21}-
Asp/Leu287{144}Thr/Ala294{152}Ser/Glu296{154}Ile/Met298{156}Lys
(not FVIIaDIK) turned out to have increased amidolytic activ-
ity compared to wild-type, we believe that a hydrophilic
environment, accomplished by the mutations Leu287{144}Thr
and Ala294{152}Ser, surrounding the Lys side chain in position
298{156} is mandatory for enhanced activity (Fig. 1). Besides
an increased amidolytic activity, FVIIa variant Val158{21}-
Asp/Leu287{144}Thr/Ala294{152}Ser/Glu296{154}Ile/Met298{156}Lys
showed speciﬁcity almost identical to that of FVIIaFXLoop.
Residue 298{156} is a part of the interface between macro-
molecular substrates and FVIIa, which is extensive and in-
volves several residues as shown by alanine scanning
mutagenesis [28]. Based on models of the ternary complex of
FVIIaTFFXa, the Gly{140}–Met{156} loops of FVIIa and
FX(a) can be pinpointed as spatially centered in the interface
between the two protease domains [18, O. H. Olsen, unpub-
lished data]. Since the models suggest that the loop is part of
both the exosite of the enzyme and the binding site of the mac-
romolecular substrate, it apparently acts as a speciﬁcity anchor
in the enzyme-substrate interaction and the Lys in position
298{156} in the FVIIa variants might be incompatible with
the corresponding Lys378{156} of zymogen FX due to charge
repulsion. This could explain the decreased activation of zymo-
gen FX. Hence, the side chain in this position appears to reﬂect
the sequential order in which these enzymes work in the coag-
ulation cascade. FVIIa (Met298 {156}) activates both FIX
(Gln{156}) and FX (Lys{156}). FIXa activates FX, whereas
FXa activates prothtrombin (Gln{156}) to thrombin. Other
speciﬁcity determinants do obviously exist, because otherwise
thrombin would for instance readily activate FX, FVII and
prothrombin. Moreover, the fact that the FVIIaFXLoop and
FVIIa variant Val158{21}Asp/Leu287{144}Thr/Ala294{152}Ser/
Glu296{154}Ile/Met298{156}Lys variants readily autoactivate also
76 J.R. Bjelke et al. / FEBS Letters 581 (2007) 71–76points in this direction. It should also be kept in mind that the
three substrates for FVIIa (FVII, FIX and FX) may bind to
slightly diﬀerent exosites. Many residues are involved in the
binding of macromolecular substrates and they are not re-
stricted to the protease domain [29,30] and even extend to
interactions between FIX/FX and TF [31]. A subgroup of res-
idues apparently confer speciﬁcity, such as that in position
{156} identiﬁed here in two super active FVIIa variants mim-
icking the Gly{140}–Met{156} loop of FX.
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